期刊文献+

口服二甲双胍血糖控制不佳的2型糖尿病患者加用地特胰岛素的疗效观察 被引量:4

The curative effect of insulin detemir as add-on therapy to previous oral metformin with poor glycemic control of type 2 diabetes
原文传递
导出
摘要 目的观察口服二甲双胍(Met)血糖控制不佳的T2DM患者加用地特胰岛素(Det)治疗的有效性。方法选取口服Met血糖控制不佳的T2DM患者70例,Met联合Det治疗12周,测定患者治疗前后FPG、2hPG、HbAl c、FC-P、C-P、BMI、BP、血脂及胰岛素抵抗指数(HOMA-IR)等。结果Met联合Det治疗12周后,FPG、2hPG、TG、LDL-C、HbAl c及HOMA-IR较治疗前下降(P<0.05);FCP及C-P升高(P<0.05)。结论口服Met血糖控制不佳的T2DM患者联合Det治疗可有效控制血糖,改善胰岛β细胞功能,调节血脂,且不增加体重。 Objective To study The curative effect of insulin detemir as add-on therapy to previous oral metformin with poor glycemic control of type 2 diabetes Methods 70 type 2 diabetic patients treated with pure oral metformin with poor glycemic control were selected to receive treatment of insulin detemir for 12 weeks. Before and after above treatments, the following parameters were measured and ealculated, including FPG, 2 hPG, HbAlc, FC-P, 2 hC-P, BMI, SBP, DBP, TG, TC, LDL-C, HDL-C, HOMA-IR. Results After 12 weeks of treatment with metforrnin combined with insulin detemir, the parameters of FPG, 2 hPO, TG, LDL-C, HbAt c and HOMA-IR were decreased (P〈0.05), and the levels of FC-P and 2 hC-P were increased (P〈 0. 05), as compared with pre-treatments. Conclusion The combination treatment of insulin detemir and metformin for the type 2 diabetic patients, who suffered from poor glycemic control, can effectively control the blood glucose, improve the function of islet cells, and regulate the blood lipids,without increasing body weight.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2014年第5期432-434,共3页 Chinese Journal of Diabetes
关键词 地特胰岛素 糖尿病 2型 二甲双胍 Insulin detemir Diabetes mulltius, type 2 Metformin
  • 相关文献

参考文献6

  • 1Meneghini L, Liebl A, Abrahamson MJ. Insulin detemir.. A his- torical perspective on a modern basal insulin analogue. Prim Care Diabetes, 2010,4 : S31-S42.
  • 2Inzucchi SE,Bergenstal RM, Buse JB, et al. Management of hy- perglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012,55 : 1577-1596.
  • 3Hermansen K, Davies M, Derezinski T, et al. A 26-week, ran- domized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with t;cpe 2 diabetes. Diabetes Care, 2006,29 : 1269-1274.
  • 4潘长玉,陆菊明,纪立农,杨文英,周智广,邹大进,姬秋和,韩萍,柳洁,李强,苏本利,李延兵,高政南,王鹏华,尹士男,董砚虎,杨涛,孙侃,李红,洪旭,林静,师静梅,杨小洁,房辉,颜晓东,无.口服降糖药治疗失效的2型糖尿病患者使用地特胰岛素的安全性和有效性SOLVE^TM国际临床观察研究中国结果报道[J].中华内科杂志,2013,52(1):11-15. 被引量:24
  • 5廖勤,梁泽容,屈春梅.两种基础胰岛素类似物——地特胰岛素与甘精胰岛素治疗2型糖尿病临床效果比较[J].实用医院临床杂志,2010,7(4):42-44. 被引量:25
  • 6H aak T, Tiengo A, Draeger E, et al. Lower within-subject vari- ability of fasting blood glucose and reduced weight gain with in- sulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab, 2005,7 : 56-64.

二级参考文献13

  • 1潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:396
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版).中华糖尿病杂志,2010,3增刊2:1-56.
  • 3Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med, 2010,362 : 1090-1101.
  • 4Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther, 2006,28 : 1569-1581.
  • 5Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta- analysis. Diabetes Res Clin Pract,2008, 81:184-189.
  • 6Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev, 2009, 25: 542-548.
  • 7Blonde L, Merilainen M, Karwe V, et al. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab, 2009,11:623-631.
  • 8Raslova K. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vasc Health Risk Manag, 2010, 6: 399-410.
  • 9Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care, 2003, 26 : 590-596.
  • 10Hermansen K, Lund P, Clemmensen K, et al. 3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study. Rev Diabet Stud, 2007,4: 89-97.

共引文献47

同被引文献46

  • 1Heise T, Nosek L, Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes[J]. Diabetes, 2004, 53(6): 1614-1620.
  • 2Klein O, Lynge J, Endabl L, et al. Albumin-bound basal insulin analogues(insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes[J]. Diabetes Obes Metab, 2007, 9(3): 290-299.
  • 3Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal insulin analogues based on isoglycaemic clamp studies[J]. Diabetes Obes Metab, 2007, 9(5): 648- 659.
  • 4American Diabetes Association. Standards of medical care in diabetes- 2014[J]. Diabetes Care, 2014, 37(Suppl 1): S14-80.
  • 5Inzuccbi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetes Care, 2015, 38(1): 140-149.
  • 6Giaccari A, Giorda CB, Riccardi G, et al. Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes(EASD) [J]. Diabetes Care, 2012, 35(10): 1364-1379.
  • 7Metzger BE, lowe LP, Dyer AR, et al. HAPO Study CooperativeRsesarch Group, Hyperglycemia and adverse pregnancy out comes[J]. N Engl J Med, 2008, 358(19): 1991-2002.
  • 8Philis-Tsimikas A. An update on the use of insulin detemir, with a focus on type 2 diabetes(drug evaluation update)[J]. Expert opin Pharmacother, 2008, 9(12): 2181-2195.
  • 9潘长玉,姬秋和,李延兵.中国2型糖尿病患者起始加用每日1次地特胰岛素治疗对体重变化的影响--SOLVETM国际研究中国亚组结果[A].中华医学会第十一次全国内分泌学学术会议论文汇编[C].广州:中华医学会,中华医学会内分泌学分会,2012:2.
  • 10Hallschmid M, Jauch-Chara K, Korn O, et al. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects[J]. Diabetes, 2010, 59(4): 110-1107.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部